Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve 1. To Consider and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals Ltd (formerly Trimurthi Limited, BSE Scrip Code: 536565) has informed BSE that its Board of Directors will meet on Thursday, 13th November 2025 at the registered office in Hyderabad. The main agenda is to consider and approve the unaudited standalone financial results for the quarter and half-year ended 30th September 2025, along with the auditor's Limited Review Report. Additionally, any other matter may be discussed with the chair's permission. The trading window for designated persons and their immediate relatives is closed from 1st October 2025 until 48 hours after the board meeting concludes.
This is a routine regulatory filing ahead of the Q2 FY26 earnings announcement. Shareholders should watch for the results on or after 13th November 2025, as the numbers could influence short-term stock sentiment, especially given the small-cap nature of the company.